PPT-Breakthroughs in IPF Management:

The Next Steps in Individualizing Treatment Learning Objectives As a result of attending this activity participants should be able to Select appropriate therapies that reflect current evidence and or widely accepted guidelines that are individualized to patients . (ILD). Mike McFarlane (CT1). 12/5/12. SLIME. What we’ll cover. Definition. Different types of ILD. Pathophysiology. Presentation. Investigations. Management. Prognosis. Clinical Scenario. Summary. What we won’t.... PULMONARY FIBROSIS MANAGEMENT STRATEGIES I. NOVEMBER 13, 2015. Managing comorbidity. Disclosures. . Scientific Advisory Board and speaker’s fees. Biogen. Idec, . Boehringer. . Ingelheim. ,. Gilead, . Diagnosing Idiopathic Pulmonary Fibrosis. FACULTY. Title. Affiliation. Learning Objectives. Explain the considerations associated with . clinical evaluation, imaging, and . biopsy. , in terms of differentially diagnosing . – . The need for early recognition and referral. PRC-2128. It can be difficult to separate idiopathic pulmonary fibrosis (IPF) from other conditions. IPF is a rare but fatal lung disease, with a lower survival rate than many common malignancies. Discussing Prognosis &. Goals of Care. Sonye K. . Danoff. , MD, . PhD. PULMONARY FIBROSIS. : WHAT AND . WHY. November 13, 2015. No conflict of interest relevant to this presentation. Objective of this talk. IMRE NOTH, MD. CLINICAL CARE: NEW AND EVOLVING TREATMENT STRATEGIES . NOVEMBER 14, 2015. What is “Precision” Medicine?. Precision medicine. is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.. SESSION THREE: April 27, 2018. HOW CHANGE HAPPENS. PRINCIPLE ONE: Change is Constant. More cyclical . than linear. People don’t . “manage” change. we shape it. PRINCIPLE ONE: Change is Constant. . Content. Importance. . of. . early. . diagnosis. . Initial . clues. . to. . suspect. IPF . Guidelines for Diagnosis. Diagnostic algorithm for IPF. . Exclusion of other known causes . Other tests and tools . Diagnosing Idiopathic Pulmonary Fibrosis. FACULTY. Title. Affiliation. Learning Objectives. Explain the considerations associated with . clinical evaluation, imaging, and . biopsy. , in terms of differentially diagnosing . 56-year-old Hispanic female with a family history of aortic aneurysm underwent a routine chest CT to assess her aorta. No respiratory symptoms. Medical history . h/o SVT. Type 2 diabetes mellitus. Hypertension. January 2021. Summary - orvepitant first in class/category, novel treatment for debilitating chronic cough associated with the terminal orphan condition idiopathic pulmonary fibrosis. The NeRRe management team recently sold KaNDy Therapeutics to Bayer in a deal valued >$1b. When using our slides, please retain the source attribution:. These slides may not be published, posted online, or used in commercial presentations without permission. . Please contact . pce@practicingclinicians.com. for Fibrosis & Oncology. Corporate Presentation – April 2021. Disclaimer. This document has been prepared by Nuformix plc (the "Company") and is being . made available for the sole purpose of providing the recipients with background information about the Company. It. Department. of . Diseases. of the . Thorax. , Ospedale GB . Morgagni. , Forlì (I). Department. of . Respiratory. . Diseases. & . Allergy. , . Aarhus. . University. Hospital, . Aarhus. (DK).